tetano
Editor, Senior Moderator
Cancers (Basel)
. 2022 Jan 22;14(3):558.
doi: 10.3390/cancers14030558.
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
Bartosz Puła[SUP] 1 [/SUP], Katarzyna Pruszczyk[SUP] 1 [/SUP], Ewa Pietrusza[SUP] 2 [/SUP], Marta Morawska[SUP] 3 4 [/SUP], Weronika Piszczek[SUP] 5 [/SUP], Elżbieta Kalicińska[SUP] 6 [/SUP], Agnieszka Szeremet[SUP] 6 [/SUP], Jagoda Tryc-Szponder[SUP] 7 [/SUP], Ewa Wąsik-Szczepanek[SUP] 8 [/SUP], Joanna Drozd-Sokołowska[SUP] 9 [/SUP], Helena Krzemień[SUP] 10 [/SUP], Aleksandra Rejus[SUP] 11 [/SUP], Małgorzata Gajewska[SUP] 12 [/SUP], Kamil Wiśniewski[SUP] 1 [/SUP], Maciej Wysocki[SUP] 1 [/SUP], Alan Majeranowski[SUP] 13 14 [/SUP], Ewa Paszkiewicz-Kozik[SUP] 15 [/SUP], Paweł Steckiewicz[SUP] 16 17 [/SUP], Łukasz Szukalski[SUP] 18 [/SUP], Łukasz Bołkun[SUP] 19 [/SUP], Monika Długosz-Danecka[SUP] 2 [/SUP], Krzysztof Giannopoulos[SUP] 3 4 [/SUP], Krzysztof Jamroziak[SUP] 9 [/SUP], Ewa Lech-Marańda[SUP] 1 [/SUP], Iwona Hus[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe.
Methods: We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection.
Results: At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; p = 0.02), advanced age (>65 years; p = 0.04), low hemoglobin concentration (≤10 g/dl; p = 0.0001), low platelets (<100 × 109/L; p = 0.003), and elevated lactate dehydrogenase level (LDH; p = 0.014) had an increased risk of death due to COVID-19. Neither CLL treatment status (treatment naïve vs. treated) nor the type of CLL-directed treatment had impact on the SARS-CoV-2 related risk of death. The multivariate survival analysis showed that advanced age (p = 0.009) and low platelet count (p = 0.0001) were associated with significantly shorter patients' overall survival.
Conclusions: SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
Keywords: COVID-19; SARS-CoV-2; chronic lymphocytic leukemia; infection; prognosis.
. 2022 Jan 22;14(3):558.
doi: 10.3390/cancers14030558.
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia
Bartosz Puła[SUP] 1 [/SUP], Katarzyna Pruszczyk[SUP] 1 [/SUP], Ewa Pietrusza[SUP] 2 [/SUP], Marta Morawska[SUP] 3 4 [/SUP], Weronika Piszczek[SUP] 5 [/SUP], Elżbieta Kalicińska[SUP] 6 [/SUP], Agnieszka Szeremet[SUP] 6 [/SUP], Jagoda Tryc-Szponder[SUP] 7 [/SUP], Ewa Wąsik-Szczepanek[SUP] 8 [/SUP], Joanna Drozd-Sokołowska[SUP] 9 [/SUP], Helena Krzemień[SUP] 10 [/SUP], Aleksandra Rejus[SUP] 11 [/SUP], Małgorzata Gajewska[SUP] 12 [/SUP], Kamil Wiśniewski[SUP] 1 [/SUP], Maciej Wysocki[SUP] 1 [/SUP], Alan Majeranowski[SUP] 13 14 [/SUP], Ewa Paszkiewicz-Kozik[SUP] 15 [/SUP], Paweł Steckiewicz[SUP] 16 17 [/SUP], Łukasz Szukalski[SUP] 18 [/SUP], Łukasz Bołkun[SUP] 19 [/SUP], Monika Długosz-Danecka[SUP] 2 [/SUP], Krzysztof Giannopoulos[SUP] 3 4 [/SUP], Krzysztof Jamroziak[SUP] 9 [/SUP], Ewa Lech-Marańda[SUP] 1 [/SUP], Iwona Hus[SUP] 1 [/SUP]
Affiliations
- PMID: 35158826
- DOI: 10.3390/cancers14030558
Abstract
Background: The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe.
Methods: We performed a retrospective study on 188 chronic lymphocytic leukemia patients (CLL) with COVID-19 infection.
Results: At the time of infection 51 patients (27.1%) were treated with Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) with anti-CD20 antibodies while 37 patients (19.7%) received venetoclax. In total, 111 patients (59.0%) required hospitalization and 50 patients (26.5%) died due to COVID-19. Patients with poor performance status (ECOG >1; p = 0.02), advanced age (>65 years; p = 0.04), low hemoglobin concentration (≤10 g/dl; p = 0.0001), low platelets (<100 × 109/L; p = 0.003), and elevated lactate dehydrogenase level (LDH; p = 0.014) had an increased risk of death due to COVID-19. Neither CLL treatment status (treatment naïve vs. treated) nor the type of CLL-directed treatment had impact on the SARS-CoV-2 related risk of death. The multivariate survival analysis showed that advanced age (p = 0.009) and low platelet count (p = 0.0001) were associated with significantly shorter patients' overall survival.
Conclusions: SARS-CoV-2 infection in CLL patients is associated with poor outcome regardless of administered CLL-directed treatment.
Keywords: COVID-19; SARS-CoV-2; chronic lymphocytic leukemia; infection; prognosis.